Latest Conference Articles

Tian Zhang, MD, discusses the goal of the ongoing PDIGREE trial examining nivolumab and ipilimumab plus cabozantinib in patients with metastatic untreated renal cell cancer.

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

Rajneesh Nath, MD, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia.

Atish D. Choudhury, MD, PhD, discusses the rationale behind combining pembrolizumab with radium-223 in patients with metastatic castration-resistant prostate cancer as part of a phase 2 clinical trial.

Anna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.

YunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.

Sairah Ahmed, MD, discusses the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory large B-cell lymphoma (LBCL) who achieved complete remission (CR) to any prior treatment versus those who were primary refractory.

Mitchell E. Horwitz, MD, discusses the use of omidubicel versus standard myeloablative umbilical cord blood transplant in patients with hematologic malignancies.

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.

Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.

Mary Jo J. Fidler, MD, discusses the potential utility of circulating tumor DNA to inform treatment escalation in lung cancer.

Rogerio C. Lilenbaum, MD, discusses the challenges of integrating telehealth services in lung cancer.

Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.

Hossein Borghaei, DO, MS, discusses selecting between single-agent versus combination therapies in lung cancer.

Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.

Martin Reck, MD, PhD, discusses the efficacy of maintenance atezolizumab in patients with extensive-stage small cell lung cancer.

Stephen Liu, MD, discusses emerging research on antibody–drug conjugate in non–small cell lung cancer that were presented during the 2020 World Conference on Lung Cancer.

Vamsidhar Velcheti, MD, discusses the results from the primary analysis of the CodeBreaK 100, which examined sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Margarita Majem, MD, PhD, discusses the patient-reported outcomes with osimertinib in EGFR-mutated non–small cell lung cancer from the pivotal phase 3 ADAURA trial.

Joshua K. Sabari, MD, discusses updated results from the phase 1 CHRYSALIS trial examining amivantamab in patients with non–small cell lung cancer whose tumors harbored EGFR exon 19 deletion or L858R mutations.

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

Andrew Zhu, MD, PhD, discusses the final overall survival results from the phase 3 ClarIDHy trial in previously treated patients with IDH1-mutated cholangiocarcinoma.

Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

3

2

1

Satya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.

John H. Strickler, MD, discusses the rationale for the phase 2/3 MOUNTAINEER-02 trial in HER2-positive gastric/gastroesophageal junction cancer.

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.